Swander Pace Capital sells pharma company for $750m

The San Francisco-based firm has exited the company after five years

San Francisco-based Swander Pace Capital has sold Insight Pharmaceuticals to Prestige Brands for $750 million.

The sale of Insight represents the firm’s second successful platform investment in the OTC industry.

Sources familiar with the transaction say that the deal will generate a 4x return.

Swander Pace and its representatives declined to comment on the transaction.

Insight Pharmaceuticals is the maker of several over the counter personal health brands including e.p.t®, a home pregnancy testing brand.

The Ontario Teachers’ Pension Plan was a co-investor in the company when Swander Pace acquired Insight from Allied Capital Corp., a listed business development company in 2009.

Prior to ownership by Allied, the company was held by Catterton Partners.

In April, Swander closed its fifth buyout fund – SPC Partners V on $350 million, according to Private Equity International’s research and analytics division.